Liminatus Pharma ( (LIMN) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Liminatus Pharma has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for this delay is the inability to complete financial statements in time to secure the necessary reviews and signatures. The company anticipates that the report will be filed within five calendar days following the original due date. Liminatus Pharma does not expect any significant changes in its financial results compared to the previous fiscal year. The company remains committed to compliance, with CEO Chris Kim signing off on the notification.
More about Liminatus Pharma
Average Trading Volume: 44,798
Technical Sentiment Signal: Sell
Current Market Cap: $46.46M
Find detailed analytics on LIMN stock on TipRanks’ Stock Analysis page.